|
|
Bristol-Myers Squibb Co.
|
 |
||||||||
|
 |
  |
 |
|
|
||
 |
 |
 
|
return to message board, top of board |
Re: BMO - BMY:Investor Lunch Takeaways: Steady Progress as Investors Eye 2025 Targets Besides Opdualag, possible windfalls: Sotyktu, Abecma Thank you Celgene: deucravacitinib, ide-cel Still hopefull for "outta nowhere"... June 8, June 13, or see you in September? |
||||||||||||
|
|
return to message board, top of board |
